Evidence map›Paper›PMID 25002815›Full record

ArticleBioinformatics and biology insights2014

In silico studies of medicinal compounds against hepatitis C capsid protein from north India.

Shilu Mathew, Muhammad Faheem, Govindaraju Archunan, Muhammad Ilyas, Nargis Begum, Syed Jahangir, Ishtiaq Qadri, Mohammad Al Qahtani, Shiny Mathew

Open access · goldAbstract read
In one paragraph

Article in Bioinformatics and biology insights, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
0.4field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 15 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Review
  9. Article
  10. Hepatitis C virus and neurological damage.World journal of hepatology · 2016
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 2 countries.

Shilu MathewPost Graduate Department of Biotechnology, Jamal Mohamed College, Tiruchirappalli, India. ; Center of Excellence in Genomic Medicine Research, King Abdulaziz University, Jeddah, Saudi Arabia. ; Department of Animal Science, Bharathidasan University, Tiruchirappalli, India.
Muhammad FaheemDepartment of Biochemistry, King Abdul Aziz University, Jeddah, Saudi Arabia.
Govindaraju ArchunanDepartment of Animal Science, Bharathidasan University, Tiruchirappalli, India.
Muhammad IlyasPost Graduate Department of Botany, Jamal Mohamed College, Tiruchirappalli, Tamil Nadu, India.
Nargis BegumPost Graduate Department of Biotechnology, Jamal Mohamed College, Tiruchirappalli, India.
Syed JahangirPost Graduate Department of Biotechnology, Jamal Mohamed College, Tiruchirappalli, India.
Ishtiaq QadriKing Fahd Medical Research Center, King Abdul Aziz University, Jeddah, Saudi Arabia.
Mohammad Al QahtaniCenter of Excellence in Genomic Medicine Research, King Abdulaziz University, Jeddah, Saudi Arabia.
Shiny MathewDepartment of Multimedia Technology, Karunya University, Coimbatore, India.
King Abdulaziz University · SABharathidasan University · INKing Abdul Aziz University Hospital · SA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hepatitis viral infection is a leading cause of chronic hepatitis, cirrhosis, and hepatocellular carcinoma (HCC). Over one million people are estimated to be persistently infected with hepatitis C virus (HCV) worldwide. As capsid core protein is the key element in spreading HCV; hence, it is considered to be the superlative target of antiviral compounds. Novel drug inhibitors of HCV are in need to complement or replace the current treatments such as pegylated interferon's and ribavirin as they are partially booming and beset with various side effects. Our study was conducted to predict 3D structure of capsid core protein of HCV from northern part of India. Core, the capsid protein of HCV, handles the assembly and packaging of HCV RNA genome and is the least variable of all the ten HCV proteins among the six HCV genotypes. Therefore, we screened four phytochemicals inhibitors that are known to disrupt the interactions of core and other HCV proteins such as (a) epigallocatechin gallate (EGCG), (b) ladanein, (c) naringenin, and (d) silybin extracted from medicinal plants; targeted against active site of residues of HCV-genotype 3 (G3) (Q68867) and its subtypes 3b (Q68861) and 3g (Q68865) from north India. To study the inhibitory activity of the recruited flavonoids, we conducted a quantitative structure-activity relationship (QSAR). Furthermore, docking interaction suggests that EGCG showed a maximum number of hydrogen bond (H-bond) interactions with all the three modeled capsid proteins with high interaction energy followed by naringenin and silybin. Thus, our results strongly correlate the inhibitory activity of the selected bioflavonoid. Finally, the dynamic predicted capsid protein molecule of HCV virion provides a general avenue to target structure-based antiviral compounds that support the hypothesis that the screened inhibitors for viral capsid might constitute new class of potent agents but further confirmation is necessary using in vitro and in vivo studies.

Indexed as

capsid proteindockinghepatitis C virushepatocellular carcinomainhibitors

Identifiers

PMID25002815
PMCPMC4076477
OpenAlexW2064159998

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.